

Online Supplement - Table 2. Characteristics of cancer patients receiving myelosuppressive chemotherapy from 2010-2016, by receipt of CSF prophylaxis in first cycle

	Receipt of Prophylaxis		
	Overall	Yes	No
	(n=142,730)	(n=82,547)	(n=60,183)
Patient			
Age (years), mean (SD)	55.7 (10.8)	55.1 (10.8)	56.4 (10.7)
Male, %	7.6%	4.4%	12.0%
Chronic Comorbidities, %			
Cardiovascular Disease	12.1%	10.4%	14.4%
Diabetes	13.0%	11.9%	14.5%
Liver Disease	4.9%	4.2%	5.9%
Lung Disease	11.2%	10.0%	12.8%
Osteoarthritis	9.2%	9.2%	9.1%
Renal Disease	3.1%	2.7%	3.6%
Rheumatoid Disease	1.5%	1.5%	1.4%
Thyroid Disease	13.2%	13.6%	12.5%
Body Weight and Nutritional Status, %			
Obesity	10.1%	8.9%	11.7%
Malnutrition	1.4%	0.9%	2.1%
Proxies for Health Status, %			
Hospice Care	0.3%	0.3%	0.3%
SNF	1.0%	0.7%	1.3%
Hospice or SNF	1.3%	1.0%	1.7%
Proxies for Physical Function, %			
Use of Hospital Bed	0.3%	0.2%	0.3%
Use of Supplemental Oxygen	2.7%	2.2%	3.4%
Use of Walking Aid	1.8%	1.5%	2.1%
Use of Wheel Chair	0.4%	0.3%	0.5%
Hx of Other Conditions/Events Prior to Chemotherapy Course, %			
Anemia	18.7%	14.5%	24.6%
Neutropenia	2.6%	3.5%	1.3%
Infection	52.5%	53.3%	51.5%
Recent Surgery	84.5%	83.3%	86.1%
Hospitalization for Any Reason	41.3%	31.5%	54.8%
Chemotherapy	3.9%	4.2%	3.5%
Radiation Therapy	8.4%	5.9%	11.8%
Pre-Chemotherapy Expenditure (\$), mean (SD)	40,869 (35,361)	38,118 (32,168)	44,627 (38,959)
Cancer-Chemotherapy			
Regimen, %			
Non-metastatic breast: TC	23.1%	24.5%	21.0%
Non-metastatic breast: TAC	3.9%	6.1%	1.0%
Non-metastatic breast: TCH	10.3%	11.2%	9.0%
Non-metastatic breast: dose-dense AC/AC-T	23.7%	36.1%	6.6%
Non-metastatic colorectal: FOLFOX	13.9%	2.5%	29.6%
Non-metastatic lung: CAR + PAC	4.6%	2.2%	7.9%
NHL: CHOP	1.6%	1.8%	1.3%
NHL: CHOP-R	9.3%	11.2%	6.8%
Non-metastatic ovarian: CAR + PAC	9.6%	4.3%	16.9%